From Images to Insight: Qureight’s AI-Powered Platform for Precision Clinical Trials

•  Introducing Qureight’s end-to-end imaging ecosystem spanning imaging CRO services, central reads and AI-powered quantitative biomarkers
• Important lessons from recent IPF and PPF studies demonstrating how imaging is improving patient selection, endpoint assessment and trial efficiency
• How integrated imaging and biomarker strategies are shaping the next generation of antifibrotic clinical trials
• Why fibrosis burden is the principal structural imaging biomarker for antifibrotic drug development and the leading candidate imaging endpoint 

Speakers:

Simon LF Walsh

Chief Scientific Officer

Qureight

Steven Bishop

Chief Medical Officer

Qureight